ValenzaBio Partners with ProBioGen to Maximize Cell Line Productivity and Licenses GlymaxX®

BERLIN, Germany and BETHESDA, MD, USA, July 27, 2021 / B3C newswire / -- ProBioGen and ValenzaBio today jointly announced the initiation of a cell line development project involving the application of ProBioGen's proprietary GlymaxX technology.

ValenzaBio's VB119 is a clinical-stage antibody for which ProBioGen will generate a new CHO-based expression system. Besides the CHO.RiGHT® cell line development platform, ProBioGen will apply its ADCC modulating GlymaxX technology. GlymaxX enables a fine tuning of the fucose content of the antibody towards the originator molecule's fucose content. The GlymaxX technology is easy to use and its flexibility in terms of fucosylation adjustment enables its application for innovative molecules as well as for biosimilar projects.

"We are very excited to enter into this agreement with ValenzaBio", said ProBioGen's Chief Scientific Officer Volker Sandig. "Being entrusted with such a project underlines the value of our cell line development expertise and technologies we have developed in the past decades."

Tatyana Touzova, Chief Operating Officer at ValenzaBio, added: "The conversion to a new expression system could help ensure VB119 reaches its full potential for patients. ProBioGen possesses a unique set of experiences and technologies using their GlymaxX platform. We are privileged to partner with such an impressive group of scientists and advance a program that we believe can be an important new therapy for patients."

About ProBioGen
ProBioGen is a specialist in the development and manufacturing of complex therapeutic proteins.
The combination of ProBioGen's CHO.RiGHT® expression platform and state-of-the-art process development platforms, together with intelligent and innovative product-specific technologies yield biologics with optimized properties.
Rapid and integrated cell line and process development, comprehensive analytical development and robust GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen has been operational for more than 27 years. At two locations in Berlin, more than 200 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work.

About ValenzaBio
ValenzaBio is a privately held biopharmaceutical company focused on developing safe and effective therapies for autoimmune and inflammatory diseases. The company is advancing a pipeline of differentiated monoclonal antibodies targeting clinically validated mechanisms of action, in order to provide improved therapies for patients with limited treatment options. ValenzaBio's lead program, VB119, is being developed for the treatment of membranous nephropathy (MN), followed by VB421, which is being developed for the treatment of thyroid eye disease (TED).

Contacts

ProBioGen
Dr. Gabriele Schneider
Chief Business Officer
cmo@probiogen.de 
+49 (0)30 3229 35 100
www.probiogen.de

ProBioGen Press Contact
Sarah Wandrey
Corporate Communications
press@probiogen.de

ValenzaBio
Alicia Davis
THRUST Strategic Communications
alicia@thrustsc.com
www.valenzabiotech.com

Keywords: CHO Cells; Cell Line; Cell Proliferation; Cell Line Development; Cells, Cultured; Recombinant Proteins; Biological Products; Antibodies; Productivity; Antibody-Dependent Cell Cytotoxicity; Fucose; Glycosylation; Killer Cells, Natural; Biosimilar Pharmaceuticals; Technology; Commerce; Licensure; Germany; North America

Published by B3C newswire